Weggen, Sascha

A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity

Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 1,388

NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo

Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., et al. (2003) · Journal of Clinical Investigation

Alzheimer's disease research and treatmentsCholinesterase and Neurodegenerative Diseases

Cited by 634

Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier

Storck, S. E., Meister, S., Nahrath, J., Meißner, J. N., Schubert, N., Di Spiezio, A., Baches, S., Vandenbroucke, R. E., Bouter, Y., Prikulis, I., et al. (2015) · Journal of Clinical Investigation

Barrier Structure and Function StudiesAlzheimer's disease research and treatments

Cited by 477

DOGS: Reaction-Driven de novo Design of Bioactive Compounds

Hartenfeller, M., Zettl, H., Walter, M., Rupp, M., Reisen, F., Proschak, E., Weggen, S., Stark, H., & Schneider, G. (2012) · PLoS Computational Biology

Computational Drug Discovery MethodsSynthesis and Characterization of Heterocyclic Compounds

Cited by 251

The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing

Pietrzik, C. U., Busse, T., Merriam, D. E., Weggen, S., & Koo, E. H. (2002) · The EMBO Journal

Alzheimer's disease research and treatmentsCellular transport and secretion

Cited by 198

Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease

Weggen, S., & Beher, D. (2012) · Alzheimer's Research & Therapy

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 192

Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia

Hüttenrauch, M., Ogorek, I., Klafki, H., Otto, M., Stadelmann, C., Weggen, S., Wiltfang, J., & Wirths, O. (2018) · Acta Neuropathologica Communications

Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatments

Cited by 166

The concerted amyloid-beta clearance of LRP1 and ABCB1/P-gp across the blood-brain barrier is linked by PICALM

Storck, S. E., Hartz, A. M. S., Bernard, J., Wolf, A., Kachlmeier, A., Mahringer, A., Weggen, S., Pahnke, J., & Pietrzik, C. U. (2018) · Brain, Behavior, and Immunity

Alzheimer's disease research and treatmentsBarrier Structure and Function Studies

Cited by 143

Gene Dosage Dependent Aggravation of the Neurological Phenotype in the 5XFAD Mouse Model of Alzheimer’s Disease

Richard, B. C., Kurdakova, A., Baches, S., Bayer, T. A., Weggen, S., & Wirths, O. (2015) · Journal of Alzheimer’s Disease

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 142

LRP1 mediates bidirectional transcytosis of amyloid-β across the blood-brain barrier

Pflanzner, T., Janko, M. C., André-Dohmen, B., Reuss, S., Weggen, S., Roebroek, A. J. M., Kuhlmann, C. R. W., & Pietrzik, C. U. (2011) · Neurobiology of Aging

Alzheimer's disease research and treatmentsBarrier Structure and Function Studies

Cited by 141

Targeting glucocorticoid receptors prevents the effects of early life stress on amyloid pathology and cognitive performance in APP/PS1 mice

Lesuis, S. L., Weggen, S., Baches, S., Lucassen, P. J., & Krugers, H. J. (2018) · Translational Psychiatry

Alzheimer's disease research and treatmentsStress Responses and Cortisol

Cited by 85

The metalloprotease ADAMTS4 generates N-truncated Aβ4–x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer’s disease

Walter, S., Jumpertz, T., Hüttenrauch, M., Ogorek, I., Gerber, H., Storck, S. E., Zampar, S., Dimitrov, M., Lehmann, S., Lepka, K., et al. (2019) · Acta Neuropathologica

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 65

Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X

Antonios, G., Borgers, H., Richard, B. C., Brauß, A., Meißner, J., Weggen, S., Pena, V., Pillot, T., Davies, S. L., Bakrania, P., et al. (2015) · Scientific Reports

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 61

PCSK9 acts as a key regulator of Aβ clearance across the blood–brain barrier

Mazura, A. D., Ohler, A., Storck, S. E., Kurtyka, M., Scharfenberg, F., Weggen, S., Becker-Pauly, C., & Pietrzik, C. U. (2022) · Cellular and Molecular Life Sciences

Alzheimer's disease research and treatmentsBarrier Structure and Function Studies

Cited by 53

LRP1 is critical for the surface distribution and internalization of the NR2B NMDA receptor subtype

Maier, W., Bednorz, M., Meister, S., Roebroek, A., Weggen, S., Schmitt, U., & Pietrzik, C. U. (2013) · Molecular Neurodegeneration

Neuroscience and Neuropharmacology ResearchReceptor Mechanisms and Signaling

Cited by 50